สำเนาบทสนทนา 🔗
WEBVTT
00:00:00.000 --> 00:00:01.300
I'm joined today by Dr.
00:00:01.300 --> 00:00:05.820
Paul Peter Tock president and CEO of Condell Therapeutics.
00:00:06.000 --> 00:00:18.670
For those of you that don't know, Condell is a clinical stage company, but not going to be clinical stage for much longer, and that's actually a lot of what we're going to talk about today.
00:00:18.920 --> 00:00:37.210
So they just-- and correct me w- if I misspoke, but you just delivered positive phase III results, and you're now starting to build up the organization that's actually going to get your treatment in the hands of practitioners, in this case, urologists and radiation oncologists.
00:00:37.250 --> 00:00:38.530
Did I get that accurately?
00:00:39.253 --> 00:00:44.963
Yes, but I would add that we will continue to be a clinical stage company because we have a pipeline.
00:00:46.094 --> 00:00:52.404
our lead asset is really a pipeline in a product, so we continue to develop it in other indications.
00:00:52.414 --> 00:00:58.493
We have a second investigational medicine that we test in recurrent glioblastoma, brain cancer.
00:00:58.514 --> 00:01:01.573
Also very encouraging results published in top journals.
00:01:01.993 --> 00:01:06.664
And we also have a discovery capability that we don't talk a lot about because we have so much data.
00:01:07.424 --> 00:01:08.224
but you are right.
00:01:08.284 --> 00:01:19.813
The most important inflection point for this year the BLA submission, the biological license application submission, which means we are at the same time preparing for launch excellence.
00:01:20.525 --> 00:01:21.085
Wonderful.
00:01:21.096 --> 00:01:34.736
So in plain terms, just so everybody understands, what does CAN-2409, your lead candidate, do differently from what a urologist or radiation oncologist is used to pr- prescribing or administering today?
00:01:35.444 --> 00:01:42.754
Yeah, we are focused on patients with localized prostate cancer elect to undergo radical treatment.
00:01:42.813 --> 00:01:45.123
That means they want to get rid of their cancer, right?
00:01:45.174 --> 00:01:46.474
Угу
00:01:46.576 --> 00:01:52.887
the tumor, which is intuitive when you think about it from a patient perspective, and they basically have two options.
00:01:53.316 --> 00:01:57.376
One is radical prostatectomy, which is major surgery.
00:01:57.387 --> 00:01:57.546
It
00:01:57.617 --> 00:01:57.977
Sure
00:01:58.367 --> 00:02:13.766
the whole prostate, and complications include the immediate, issues like urinary incontinence, erectile dysfunction, and then it may improve over time to a certain extent, but not in everybody, and it's it is an issue.
00:02:13.766 --> 00:02:18.907
But it clearly illustrates the motivation of these patients to live without cancer,
00:02:19.314 --> 00:02:19.735
Yes
00:02:19.736 --> 00:02:25.266
the alternative is to choose radical sorry radiotherapy with curative intent.
00:02:26.016 --> 00:02:27.967
the outcomes are similar.
00:02:28.806 --> 00:02:40.667
and that means actually that there is recurrence in about thirty percent, one-third of the patients which is of course a problem because it leads to symptoms due to local progression of the disease.
00:02:40.806 --> 00:02:56.627
Ultimately, if metastases develop, the symptoms due to metastases, and then these patients will get so-called salvage anti-cancer therapies like long-term hormone therapy called androgen deprivation therapy, basically chemical castration
00:02:57.669 --> 00:02:57.990
Угу
00:02:58.169 --> 00:03:02.258
It has a negative impact on quality of life in the majority of the patients.
00:03:02.269 --> 00:03:12.899
So you may live almost normal life in terms of survival during the next ten, 15 years, but it is associated with toxicity, reduced quality of life.
00:03:12.899 --> 00:03:26.110
And that is the problem that we try to solve with aglatimodgen by combining it In patients who have chosen already radiotherapy as their in principle, curative or treatment.
00:03:26.381 --> 00:03:38.830
And we try to increase the proportion of patients that will achieve that goal, that will achieve disease-free survival, and that's what we've shown in the phase three clinical trial, and it is a viral immunotherapy.
00:03:39.711 --> 00:03:53.031
also add in terms of the workflow, So what does it mean for clinical practice that really attractive here is that we are not asking physicians to redesign the treatment pathway.
00:03:54.048 --> 00:04:09.837
A, is a novel immunotherapy, as I mentioned, but operationally it can be integrated into an existing radiation therapy workflow only three localized outpatient administrations into the prostate.
00:04:10.687 --> 00:04:14.147
followed by two weeks of a tablet that patients will take orally
00:04:14.237 --> 00:04:14.598
Угу
00:04:14.742 --> 00:04:15.643
palonosetron.
00:04:15.693 --> 00:04:18.622
You can just get it in the pharmacy on prescription.
00:04:18.673 --> 00:04:29.882
And then basically we combine something scientifically quite innovative with something that is r- already straightforward and normal to implement in clinical practice
00:04:30.824 --> 00:04:31.225
Wow.
00:04:31.535 --> 00:04:33.725
That is really amazing.
00:04:33.725 --> 00:04:44.355
So congratulations, and personally, I know somebody that's actually going through this, and what y- the journey that you're describing is very accurate, and it's very, traumatic, right?
00:04:44.355 --> 00:04:48.115
So this is really an amazing piece of technology.
00:04:48.384 --> 00:04:53.995
But let's talk about how are you-- that's a it's a bit of a complex message, right?
00:04:54.004 --> 00:05:06.735
So you say shift-- The day after, your positive Phase III data readout, what actually changed at Condell organizationally?
00:05:06.745 --> 00:05:12.935
How do you go from everything is focused on leading up to this moment to what's called a, a launch readiness phase?
00:05:13.084 --> 00:05:13.175
Yeah.
00:05:13.475
Load full transcript
--> 00:05:14.654
Quite a lot actually.
00:05:14.654 --> 00:05:17.475
It's a very good question because we've thought a lot about this.
00:05:17.485 --> 00:05:28.084
So we waited for the phase III data, but we had done all the enabling work get ready for manufacturing, scaling up commercial manufacturing.
00:05:28.095 --> 00:05:30.495
That's a big thing, and it requires a big investment.
00:05:31.394 --> 00:05:45.274
am sure that investors would be very unhappy if at the time of a low share price, we would have diluted them very significantly, raised a lot of money to be able to scale up commercial manufacturing at risk, right?
00:05:45.331 --> 00:05:45.690
Right
00:05:45.845 --> 00:05:50.654
Because we know that two-third of the phase III clinical trials are actually not positive.
00:05:50.954 --> 00:05:51.305
Yep
00:05:51.324 --> 00:05:52.904
we did all the enabling work.
00:05:52.935 --> 00:05:55.115
We had an external partner chosen, et cetera.
00:05:55.464 --> 00:05:59.894
We waited until we had the data read out in December 2024.
00:06:00.185 --> 00:06:01.514
Then the share price went up.
00:06:01.935 --> 00:06:12.074
We did an, a financing overnight, and the next day we pressed the button of starting the whole process that we had prepared already with an external partner,
00:06:12.673 --> 00:06:12.934
Ага
00:06:13.115 --> 00:06:16.225
is Merck Millipore in Carlsbad, California.
00:06:16.264 --> 00:06:16.454
So
00:06:16.478 --> 00:06:16.848
Yeah
00:06:17.035 --> 00:06:17.314
thing.
00:06:17.435 --> 00:06:19.154
Financing CMC.
00:06:19.615 --> 00:06:19.935
Yep
00:06:20.035 --> 00:06:27.764
the mindset in the company changed from being just an R&D organization, not just, it's also a big and great thing,
00:06:28.197 --> 00:06:28.466
Sure
00:06:28.485 --> 00:06:33.665
Really starting to prepare for the po- the possibility of commercialization.
00:06:33.675 --> 00:06:39.774
So we did that in parallel to the manufacturing Prepare for execution on multiple levels.
00:06:40.653 --> 00:07:01.204
we deliberately did not say,"Let's now build a traditional large pharma commercial organization." So it's the same way of thinking that we had about scaling up manufacturing at the right time in an externalized model that we apply when we think about commercialization, unlike many other co- biotech companies.
00:07:01.213 --> 00:07:12.483
So we chose a dynamic model adding capabilities regulatory, access, launch readiness milestones,
00:07:12.869 --> 00:07:14.168
Угу
00:07:14.473 --> 00:07:16.774
new milestones that were being reached.
00:07:16.793 --> 00:07:23.454
And that gave us the speed without creating a large fixed cost infrastructure prematurely
00:07:24.418 --> 00:07:24.627
Right.
00:07:24.788 --> 00:07:31.257
So you're setting up these even pre phase three readout, you essentially have-- And I guess you would have to do this, right?
00:07:31.257 --> 00:07:39.627
You have these trigger points where if things go the way you're hoping, this is lined up, and in your case, it's overnight, which is very impressive, so congratulations on that.
00:07:39.968 --> 00:07:42.077
And then can you tell me what Excuse me.
00:07:42.088 --> 00:07:57.608
As it relates to the field infrastructure, field organization when you say dynamic, I understand what you mean about it sounds like continuing to establish triggers for ramping up various areas like regulatory affairs.
00:07:58.348 --> 00:08:05.148
Most biotech leaders that I talk to inherit some type of field infrastructure, and you're really building this from scratch.
00:08:05.148 --> 00:08:07.127
So how are you thinking about that?
00:08:07.148 --> 00:08:07.927
Where to start?
00:08:07.937 --> 00:08:09.208
Is it med affairs first?
00:08:09.208 --> 00:08:10.538
Is it commercial first?
00:08:10.908 --> 00:08:13.168
The size, the locations, et cetera.
00:08:13.168 --> 00:08:16.017
Can you just share how you think about building something from zero?
00:08:16.838 --> 00:08:17.077
Yeah.
00:08:17.077 --> 00:08:28.038
But when I s-speak about dynamic, it also means that it's not only based on, a distinction between what I call committed spend in the budget versus trigger spend.
00:08:28.067 --> 00:08:31.778
You rightly used the term trigger, and I very much think like that.
00:08:32.128 --> 00:08:38.038
You try to de-risk and then be ready to trigger the next investment to create value for shareholders.
00:08:38.038 --> 00:08:40.898
But it also means that we work with external partners.
00:08:40.937 --> 00:08:49.265
We, Own the whole commercial infrastructure in-house prematurely, and maybe we will never actually completely bring it into house.
00:08:49.275 --> 00:08:53.535
Similar to how we work with a, a chief-- with a CRO organization
00:08:53.587 --> 00:08:53.947
Right
00:08:54.096 --> 00:08:58.355
clinical development for our phase three trial in non-small cell lung cancer.
00:08:58.735 --> 00:09:04.316
Similar to how we work with a CDMO, Merck Millipore for manufacturing.
00:09:04.446 --> 00:09:07.326
So we use the same model for commercialization.
00:09:07.336 --> 00:09:12.395
So you asked me the question, where do you start now, medical affairs or commercial?
00:09:12.775 --> 00:09:17.957
And I don't think in terms of either/or, So th-this is different, I think.
00:09:18.168 --> 00:09:24.278
You start with the patient journey, and you start then to work backwards.
00:09:24.607 --> 00:09:25.817
That's how I think about it.
00:09:25.837 --> 00:09:32.028
B- So because you have some-something to sell, you need engagement.
00:09:32.333 --> 00:09:32.714
Yes
00:09:32.717 --> 00:09:41.821
You need to build the relationships with the key external experts or KOLs, key opinion leaders, A lot in that field, and we are very well connected at this time.
00:09:42.280 --> 00:09:51.380
And you need to invest in understanding the treatment pathway the market access preparation, and all of this is ongoing.
00:09:52.000 --> 00:09:55.831
And then commercial execution skills
behind these principles.
00:09:56.311 --> 00:10:02.301
So for me, the important thing is that all of those functions are working from one strategy, right?
00:10:02.301 --> 00:10:03.811
So it's not either/or.
00:10:04.841 --> 00:10:19.650
Cadel, for example, has already expanded its MSL presence and scientific engagement while simultaneously building access and commercial capabilities in an-- part or largely externalized model.
00:10:19.910 --> 00:10:23.870
We did bring in the chief commercial officer in-house, senior leader
00:10:24.274 --> 00:10:25.715
Угу
00:10:25.870 --> 00:10:34.623
I like to build companies actually top-down Than the other way around, and then decide what do we really need to own in-house at which stage of development.
00:10:52.043 --> 00:11:03.802
So similarly to the outsourcing of manufacturing con-contract organizations for medical, for field, the K- is the KOL management sounds like that was a, a major initial priority.
00:11:03.802 --> 00:11:08.493
Is that being managed in-house, or is that something that you're also contracting out for?
00:11:09.259 --> 00:11:12.558
Yeah, l-largely externalized, although we are very much involved.
00:11:12.589 --> 00:11:13.933
We call it the one team approach.
00:11:13.933 --> 00:11:15.849
So I'm personally very much involved.
00:11:15.869 --> 00:11:17.298
I'm a physician scientist.
00:11:17.298 --> 00:11:18.658
I'm a senior academic.
00:11:18.668 --> 00:11:19.849
We're very well connected.
00:11:19.849 --> 00:11:23.019
Same is true for my-- of my leadership team.
00:11:23.028 --> 00:11:26.579
So we're very close to, external partners.
00:11:26.579 --> 00:11:44.009
But structurally we work with external parties like, for the market research early on Globe Life Sciences for the commercial strategy, almost like an initial virtual chief commercial officer organization, Idea Pharma.
00:11:44.918 --> 00:11:47.839
increasingly we have started to work with Eversana.
00:11:47.859 --> 00:11:56.249
That brings all the commercial capabilities, and we see-- oversee it with our team, including our recently appointed chief commercial officer.
00:11:56.860 --> 00:11:58.071
That's fascinating, right?
00:11:58.071 --> 00:12:07.610
'Cause you're really talking about running a very agile and lean organization where you're bringing in the senior leadership.
00:12:07.671 --> 00:12:14.311
I'm assuming similarly to the CCO, you've done similarly in manufacturing and in, in regulatory, right?
00:12:14.321 --> 00:12:19.860
To control these levers and keep your partners focused in the right direction.
00:12:20.181 --> 00:12:26.980
Are you feeling like this is helping you move at the speed that you're required to move at to achieve success?
00:12:27.623 --> 00:12:28.863
Yeah, it's a great question.
00:12:28.883 --> 00:12:31.562
Clear advantage is that you don't build a big fixed cost
00:12:31.663 --> 00:12:31.962
Sure
00:12:33.086 --> 00:12:43.616
because we've seen many recent examples even in our space of viral immunotherapies where there were some delays, for example, due to interaction with the FDA reasons.
00:12:43.667 --> 00:12:45.866
There may be issues in manufacturing.
00:12:45.866 --> 00:12:46.517
It's biology.
00:12:46.517 --> 00:12:55.076
You cannot predict everything, and then you have this whole commercial organization and a commercial sales force working, and you need to pay them to do nothing and keep them engaged.
00:12:55.479 --> 00:12:55.788
Right
00:12:56.037 --> 00:13:05.037
we have invented almost a whole new model that is not that new because it is normal already to work with CROs in development, the CDMOs.
00:13:05.106 --> 00:13:09.547
It's the same principle, but I don't think many biotech companies have worked like this.
00:13:09.976 --> 00:13:17.677
But an advantage is also the speed, to your point, because if you want to hire the right people, actually takes a lot of time.
00:13:18.001 --> 00:13:19.081
Угу
00:13:19.206 --> 00:13:26.023
start to work with external organizations that have all these people ready to go, you just press the button Are available to go.
00:13:26.052 --> 00:13:35.972
So it has helped us actually to not compromise in terms of speed or quality while being able to control the co- control the cost in a very measured way
00:13:36.923 --> 00:13:37.483
Yeah.
00:13:37.743 --> 00:13:45.722
And so-- and this also, just to be clear I should have asked about your background a little bit, but this is not your first time leading a company.
00:13:45.932 --> 00:13:55.393
I think there was Temporo you led to acquisition, Kintai, and I apologize if I'm mispronouncing any of this, and now Condell for a first launch.
00:13:55.613 --> 00:14:03.993
So are these-- is this a-- are these tactics that you've, or strategies that you've done in the past, or is this kind of new approach for you given the current landscape?
00:14:04.688 --> 00:14:06.119
No, it's not a new approach for me.
00:14:06.168 --> 00:14:11.889
Maybe it goes even back further because I was a senior leader at GlaxoSmithKline,
00:14:12.211 --> 00:14:12.961
Oh, okay
00:14:13.349 --> 00:14:15.908
I was the global head of development for the whole company.
00:14:15.908 --> 00:14:17.849
I was the chief immunology officer.
00:14:18.399 --> 00:14:24.209
And among different roles, I was also at the interface or at some point of R&D and commercial.
00:14:24.629 --> 00:14:29.849
I was on the franchise, the commercial franchise board of GSK Immuno Information.
00:14:30.688 --> 00:14:36.568
on the board of directors of ViiV Healthcare, the GSK HIV company.
00:14:37.158 --> 00:14:40.739
So I've been exposed to to commercial in, in different roles.
00:14:40.739 --> 00:14:43.438
And then I've always had my side projects actually in life.
00:14:43.818 --> 00:14:52.839
I've started and led early on in my career an occupational medicine company in the Netherlands with very big clients in the end, like AkzoNobel.
00:14:53.109 --> 00:14:57.509
That's why I d- I did that in
parallel while I was being in training to become an internist.
00:14:58.259 --> 00:15:08.829
when I was a professor of rheumatology at the Academic Medical Center in Amsterdam, I was also the managing director, the medical director of a commercial clinic in the Middle East in Dubai.
00:15:08.859 --> 00:15:09.158
So
00:15:09.379 --> 00:15:10.038
Oh, wow
00:15:10.038 --> 00:15:24.509
lot of thought to commercialization models, and I've learned over time, especially in biotech, that you always need to be very conscious about how you bring in s- fixed infrastructure and deal with a fixed cost, at the right time.
00:15:24.509 --> 00:15:33.623
And you can ex- I think you need to externalize what you really do not need to own, During a certain phase of development of a company in general.
00:15:33.702 --> 00:15:36.993
So that's a general principle that I've used throughout my career
00:15:37.513 --> 00:15:40.383
And so how do you deal with, I guess everything, right?
00:15:40.383 --> 00:15:40.942
There's nothing...
00:15:40.972 --> 00:15:43.673
Most things in life, there's pluses and minuses, right?
00:15:43.673 --> 00:15:47.182
There's, is, m- very few things that are clear all positive, right?
00:15:47.182 --> 00:15:50.842
When you're talking about externalizing, you might be talking about lack of con- control.
00:15:50.842 --> 00:15:54.133
You might be talking about, somebody supporting multiple products, right?
00:15:54.133 --> 00:15:55.572
Lack of focus.
00:15:55.663 --> 00:15:58.533
How do you deal with some of the negatives that come along with this?
00:15:58.552 --> 00:16:05.123
And then specifically around kind of training them and ensuring that they're telling the story that you want them to tell.
00:16:05.312 --> 00:16:06.173
How do you approach that?
00:16:07.246 --> 00:16:07.647
Yeah.
00:16:07.697 --> 00:16:11.537
It's really a, a one one team approach, right?
00:16:11.537 --> 00:16:17.976
So functionally, like in manufacturing, we f- we brought in the top leadership from Novartis from other...
00:16:17.996 --> 00:16:19.366
from Merck, other companies.
00:16:19.866 --> 00:16:24.167
We brought in a very strong regulatory group, a quality group, and then we externalize.
00:16:24.507 --> 00:16:29.917
And you try to create functional teams that where there's a cultural fit, right?
00:16:29.984 --> 00:16:31.423
Угу
00:16:31.527 --> 00:16:37.637
I think culture, I would probably put culture the cultural fit first more than anything else
00:16:37.924 --> 00:16:39.034
Can you describe what you mean by that?
00:16:39.990 --> 00:16:40.370
Yeah.
00:16:40.520 --> 00:16:55.557
We spent a lot of actually time to think about bringing the, the people into the company that live the values that we find important, like scientific excellence, For the community in the first place, caring for patients High-performing team behavior as well.
00:16:55.557 --> 00:16:58.537
I can-- We can do a whole interview about this topic, actually.
00:16:58.586 --> 00:17:00.147
I've published about these principles.
00:17:00.157 --> 00:17:02.336
These things are really important.
00:17:02.356 --> 00:17:04.567
Of course, experience matters, right?
00:17:04.931 --> 00:17:06.289
Угу
00:17:06.336 --> 00:17:09.666
to have people are really good at what they are doing, obviously.
00:17:10.076 --> 00:17:25.239
But we can teach, we can teach people a project, but it's much more difficult to teach other cultural aspects that I find important, like curiosity, Scientific curiosity being truly innovative, judgment, right?
00:17:25.239 --> 00:17:27.439
Many things are ultimately a judgment call.
00:17:27.838 --> 00:17:28.749
A lot about this.
00:17:29.019 --> 00:17:34.598
Create a genuine connection to the mission of the company, which is to improve patients' lives.
00:17:34.628 --> 00:17:49.729
For example, for many therapies when you think about primary, outcomes people are focused on, let's say, ORRs, overall response rates, which means you do a CT scan or an MRI, and you show that the tumor is smaller.
00:17:50.028 --> 00:17:56.899
And that may be adequate for, let's say, radiotherapy or chemotherapy, but it is really not for many immunotherapies.
00:17:56.899 --> 00:17:58.608
So actually, the tumors may grow initially.
00:17:58.788 --> 00:17:59.269
Why?
00:17:59.679 --> 00:18:04.469
Because we are replacing tumor cells by immune cells, and it can be quite difficult to distinguish.
00:18:04.469 --> 00:18:06.409
So we call that pseudoprogression.
00:18:06.878 --> 00:18:17.459
So then I ask the question, in mind our value of caring for each other and caring for patients in the first place, what is it that really matters for patients?
00:18:17.489 --> 00:18:21.969
Let's say patients with metastatic progressive lung cancer, what is their goal?
00:18:22.358 --> 00:18:25.409
They want to live longer with a good quality of life.
00:18:25.996 --> 00:18:33.506
With early localized prostate cancer, to come back to the earlier point, they want to live without evidence of recurrence of the disease
00:18:33.769 --> 00:18:35.229
Угу
00:18:35.365 --> 00:18:37.066
salvage anti-cancer therapy.
00:18:37.066 --> 00:18:42.395
So that is a-- these are examples of val-- cultural values that are that are critical.
00:18:42.405 --> 00:19:01.895
So in our one team model, as I call it, we have deliberately maintained oversight of the people that we bring in, also in an external organization that will work with us because we want people, to feel really accountable for delivering the objectives.
00:19:02.685 --> 00:19:06.395
so it's about the what, but also about the how.
00:19:06.425 --> 00:19:10.006
How do you deliver this in terms of behaviors and cultural values?
00:19:10.006 --> 00:19:12.816
So maybe that is something that is a little bit more
00:19:13.375 --> 00:19:13.596
No.
00:19:14.046 --> 00:19:15.806
than other things that are more straightforward.
00:19:16.026 --> 00:19:31.506
It's really fascinating because when you're talking-- especially as
you're talking about an organization where you're really relying on your leadership team to manage these external partners, not that it's ever not critical to have good leadership, but it's even amplified, right?
00:19:31.506 --> 00:19:38.955
Because if you have the wrong person in a role that's might be noticed by a contract organization, right?
00:19:38.955 --> 00:19:41.905
Which is different than being noticed by a director or something like that.
00:19:41.905 --> 00:19:47.165
So just practically, and this is something I've always struggled with, so I actually want to know for my own knowledge.
00:19:47.185 --> 00:19:51.125
But, how do you get to that if you're interviewing somebody?
00:19:51.155 --> 00:19:55.365
Let's say you don't have an existing relationship, you don't already know this, this person.
00:19:55.596 --> 00:20:01.496
How are you identifying that level of care, that level of patient focus, and that level of curiosity?
00:20:01.516 --> 00:20:03.966
Because it would seem if you ask anybody,"Hey, are you curious?
00:20:03.966 --> 00:20:06.385
Do you care about patients?" Most people would say yes.
00:20:06.395 --> 00:20:07.645
So how do you get to the truth?
00:20:08.468 --> 00:20:23.127
When we speak about people that we bring in-house, we spend a lot of time actually on interviewing people, and you need to make sure that the company understands the values and the behaviors, and we spend a lot of time on that actually also in the annual performance reviews.
00:20:23.147 --> 00:20:23.438
That
00:20:23.836 --> 00:20:24.116
Угу
00:20:24.168 --> 00:20:25.178
more scary than it is.
00:20:25.178 --> 00:20:37.377
It's really like a conversation and a dialogue, and it should not be once a year, it should be actually every one-on-one meeting that you have where you also give feedback in the moment, you can-- where you can hold each other accountable.
00:20:37.448 --> 00:20:38.907
And we are not very judgmental.
00:20:38.918 --> 00:20:39.998
We are very supportive.
00:20:40.008 --> 00:20:44.881
We are a very strong community, and w- with very high engagement levels in the company.
00:20:44.911 --> 00:21:00.341
We know that because we measure it, and if we see that we need to improve something, we will create small teams to talk it through and what can we learn as leaders, and I want to make sure that people understand that we listen to them, actually, and that we all want to improve all the time.
00:21:00.341 --> 00:21:10.431
So are aligned, I think in terms of the cultural values and behaviors because we talk a lot about it also in the context of high-performing team behaviors.
00:21:10.431 --> 00:21:12.490
And then we interview people.
00:21:12.980 --> 00:21:16.621
We are looking for people who are really good at what they need to do, right?
00:21:17.050 --> 00:21:24.711
You want to have content experts, but we will also explore this, and we try to train our people how to do the right interviews.
00:21:24.740 --> 00:21:27.480
And we're also looking for people who are fun, right?
00:21:27.480 --> 00:21:34.401
I'll give you an, a strange example that, for example, the Halloween party is a big thing at Condell,
00:21:34.489 --> 00:21:35.149
I love it
00:21:35.471 --> 00:21:37.530
comes dressed up, and it's a whole big thing.
00:21:37.740 --> 00:21:43.841
I know that some of my, my, the employees now ask we have this, this big Halloween event.
00:21:43.961 --> 00:21:53.330
Would you participate, and how do you think about it?" And there's no right or wrong answer, but you get the feel for how people react also outside their comfort zone.
00:21:53.361 --> 00:21:56.171
And I think fun, having fun together is
00:21:56.497 --> 00:21:56.856
Yes
00:21:57.651 --> 00:22:05.401
Because you spend so much time together, also because it helps to build trust, so people see we are all human, including the
00:22:05.421 --> 00:22:05.810
You're right
00:22:06.841 --> 00:22:09.480
And it also unleashes creativity.
00:22:09.500 --> 00:22:12.591
So th- these are some examples of how I think about this
00:22:13.212 --> 00:22:25.673
Y- you know what's funny that you, that example that you give, Paul Peter, is so I started a fairly new role a couple of months ago, and our, my very first week there was at this major training and development conference.
00:22:25.932 --> 00:22:32.702
And what I learned about the company that I joined is every year we do a really big, really well-attended karaoke party.
00:22:33.133 --> 00:22:43.543
And it's the same thing where you're, you're at this conference, people are CEOs on stage giving talks, everybody is all buttoned up and professional, and then we do it after the last day of the conference.
00:22:44.502 --> 00:22:51.682
Not, and your clients come, but your coworkers come, and you have this big, very fun sort of bonding experience.
00:22:51.853 --> 00:23:05.512
And it's like after all of the dinners and the trainings and all of the sort of more traditional stuff, I feel like that exposed more of the soul of the company to me than any- anything else.
00:23:05.793 --> 00:23:15.873
So I love that approach of, yes, you're doing big, important things, but also we're gonna do a big deal Halloween party because it's fun and you get to know people.
00:23:16.101 --> 00:23:16.810
Yeah I agree.
00:23:16.941 --> 00:23:25.441
And that's also another advantage actually, that if you invest in the relationship before things get difficult, it's easier to have difficult conversations
00:23:25.711 --> 00:23:26.050
Yes
00:23:26.510 --> 00:23:27.911
there will always be pressure.
00:23:27.941 --> 00:23:32.000
For example, have enormous pressure to deliver on timelines.
00:23:32.030 --> 00:23:35.800
In fact, in the last six years, we did not miss a single catalyst.
00:23:35.810 --> 00:23:37.421
I don't say it's never going to happen,
00:23:37.817 --> 00:23:38.176
Right
00:23:38.330 --> 00:23:40.131
we are ambitious and we have delivered on it.
00:23:40.131 --> 00:23:42.451
And
sometimes you need to hold people accountable.
00:23:42.881 --> 00:23:46.961
And if you have a good relationship, will know and I will know that it's not personal, right?
00:23:47.060 --> 00:23:49.121
We just try to do the best for the business.
00:23:49.131 --> 00:23:53.750
If there are performance issues, we have very open conversations about this.
00:23:53.750 --> 00:23:56.401
We try to help people to improve.
00:23:56.500 --> 00:23:59.961
Sometimes we give them executive coaching to improve.
00:23:59.990 --> 00:24:07.151
And then if everything goes wrong, then of course there's no path forward and we try to help them to find another career elsewhere.
00:24:08.080 --> 00:24:09.490
but that rarely happens
00:24:10.040 --> 00:24:10.421
Yeah.
00:24:10.810 --> 00:24:23.550
So one of the people in my career who I really took a lot from was a former CEO of mine, and he would always talk about starting from a place of a- of assuming good intentions, right?
00:24:23.550 --> 00:24:31.951
I assume that I woke up this morning thinking I was going to attempt to do a good job with whatever my tasks were, and likewise with your colleagues.
00:24:32.490 --> 00:24:35.641
But what I think might be a good job might not necessarily be what you had in mind, right?
00:24:35.641 --> 00:24:50.431
So this, this knowing people, understanding them, understanding who they are more holistically, and starting from that place of assuming good intentions is something I've tried to do as I've been managing people.
00:24:50.461 --> 00:24:54.881
And I think it, it really does make a big difference versus just"Oh, God, Bob's an idiot.
00:24:54.881 --> 00:24:56.451
There he goes again." That's not the way you...
00:24:56.480 --> 00:24:57.500
Nobody wants to work like that.
00:24:58.141 --> 00:25:00.381
No, and that brings me back to the mission, right?
00:25:00.461 --> 00:25:04.851
Everybody needs to understand the mission which is for us to improve patients' lives.
00:25:05.250 --> 00:25:10.161
Patients who live with cancer have a huge unmet need and we can all get behind this enormous mission.
00:25:10.161 --> 00:25:12.111
And that's the beauty of working in this field, right?
00:25:12.141 --> 00:25:28.906
I In general can be super interesting, but it's an incredible privilege if you try to run an outstanding business and create value for your employees and for your shareholders, but at the same time, actually, where you may have a positive contribution to society.
00:25:28.926 --> 00:25:33.116
That's a, a responsibility and a privilege, and people get behind that
00:25:33.404 --> 00:25:37.454
Yeah, and even the question, the-- as you were going through your background, ViiV, right?
00:25:37.454 --> 00:25:38.365
I'm somewhat familiar.
00:25:38.365 --> 00:25:41.884
That is, has changed many lives, right?
00:25:41.894 --> 00:25:43.795
And it, and yeah.
00:25:43.807 --> 00:25:44.686
it is great.
00:25:44.697 --> 00:25:44.717
Yeah
00:25:45.325 --> 00:25:45.745
Yeah.
00:25:45.904 --> 00:25:50.055
So I know we got a little bit off of the field field operations.
00:25:50.245 --> 00:25:52.325
To be honest, that happens in almost every episode.
00:25:52.325 --> 00:25:52.894
I don't know.
00:25:52.934 --> 00:25:55.474
I'm not a, I hope they don't revoke my podcast license.
00:25:55.664 --> 00:26:06.184
But if you could, and I know this, this might be hard to see, but a year from now, two years from now, things have gone the way you're expecting and hoping them to go.
00:26:06.454 --> 00:26:19.414
Are you still maintaining that contractual model for field, or is it going to be something where at some point where you're no longer dependent on these approvals or getting into new countries it's more about execution?
00:26:19.595 --> 00:26:20.944
Are you bringing things in-house?
00:26:22.287 --> 00:26:24.697
It will probably change over time, right?
00:26:24.767 --> 00:26:28.656
We will try to do the, the right thing at the right ti- time point.
00:26:28.747 --> 00:26:31.527
We will bring in more in-house than we currently have.
00:26:31.527 --> 00:26:37.376
So after approval, we will probably bring in more senior leaders, and it's really up to the chief commercial officer.
00:26:37.906 --> 00:26:45.636
Again, I'd like to build comp-- organizations top-down, with the right leaders, and we have a great chief commercial officer, Mark Simms.
00:26:46.457 --> 00:26:52.947
so we have started the conversations of anyway, which are the first people that we want to bring in to the organization.
00:26:52.947 --> 00:26:59.676
But it's quite conceivable that also part of the commercial organization will remain outside.
00:26:59.757 --> 00:27:07.576
My current bias or expectation is that after approval, we will probably bring in the sales force in-house.
00:27:07.730 --> 00:27:13.290
At that time point, probably you want to have these people report into the organization and be part of it.
00:27:13.941 --> 00:27:20.911
But I think the most important if you th- ask a-- if you think about the question, what does succe-success look like, right?
00:27:21.228 --> 00:27:22.668
Угу
00:27:22.830 --> 00:27:29.030
approval then I think what I'm planning for is that eligible patients can actually get the treatment.
00:27:29.641 --> 00:27:42.780
That the overarching principle, that the right physicians understand the data the priority accounts, know how to identify patients and integrate the treatment into, the workflow.
00:27:42.800 --> 00:27:50.131
The reimbursement is functioning and we are learning rapidly from the field, so it will also be like an iterative process, right?
00:27:50.191 --> 00:27:56.971
And that revenue ultimately follows, from successful patient access, which is critical.
00:27:57.471 --> 00:28:02.381
And I think it shouldn't be confused with the purpose of the organization, which is to improve patients' lives.
00:28:02.381 --> 00:28:12.441
But these things should go hand in hand, and I think increasingly we will do this having more,
in-house capabilities than before approval
00:28:12.833 --> 00:28:13.182
Yeah.
00:28:13.492 --> 00:28:18.313
It's always amazing to me and, just it's so complex, right?
00:28:18.313 --> 00:28:22.782
This-- It's not like you're launching, a new phone or something where,"Hey, I have a product.
00:28:22.782 --> 00:28:39.242
I just ship it out to the store, and now it's there." It's like at one point I was talking to companies working more on the regulatory side, and somebody in regulatory is"Listen, if we can't get our label approved, the drug might as well not even exist in a country'cause no patient is going to take it and no patient will benefit for it." So there's...
00:28:39.702 --> 00:28:41.633
And there's the same thing with the manufacturing, right?
00:28:41.633 --> 00:28:43.603
And the distribution and on.
00:28:43.613 --> 00:28:46.073
Congratulations on your progress to date.
00:28:46.093 --> 00:28:47.403
It's very, I don't know.
00:28:47.413 --> 00:28:56.803
I find it very inspiring to talk to somebody who's been through it, managing this complex thing, but clearly unfazed by the stressors that can can come with it.
00:28:57.875 --> 00:28:58.394
Well, thank you.
00:28:58.394 --> 00:29:00.424
Maybe building on what you just said, right?
00:29:00.495 --> 00:29:03.035
I learned this a long time ago at GSK in particular.
00:29:03.404 --> 00:29:10.194
It's critical to get ready not only for the regulators, but also in the first place for the patients.
00:29:10.404 --> 00:29:17.984
So we work very closely with patients and patient organizations with healthcare professionals with the payers, right?
00:29:17.984 --> 00:29:23.224
So you need to get all these things right way before approval and, that's what we are doing.
00:29:23.560 --> 00:29:23.841
Yeah.
00:29:24.070 --> 00:29:27.361
Just out of curiosity, how are you finding this Because you're in Portugal, right?
00:29:27.361 --> 00:29:31.101
And you said a lot of the company is operating in Massachusetts.
00:29:31.580 --> 00:29:38.851
How are you finding this remote world being different than maybe what you had experienced in the past?
00:29:39.793 --> 00:29:40.032
Yeah.
00:29:40.043 --> 00:29:41.573
I've always worked like this actually.
00:29:41.583 --> 00:29:47.633
So I work full-time in the US, but part-time remotely, and the same is true for my team.
00:29:47.673 --> 00:29:55.272
I did the IPO actually, remotely from Cambridge, England, being in a very serious lockdown.
00:29:55.333 --> 00:29:58.813
I don't know whether you know this, but the lockdown in England was very serious.
00:29:59.153 --> 00:30:05.762
So I was just in my office working until midnight presenting, and then every midnight we had a board meeting.
00:30:06.009 --> 00:30:06.278
Oh
00:30:06.383 --> 00:30:06.633
how I
00:30:06.638 --> 00:30:06.858
my gosh.
00:30:07.123 --> 00:30:07.133
IPO.
00:30:07.798 --> 00:30:08.288
Wow
00:30:08.583 --> 00:30:10.853
and then I recruited my leadership team.
00:30:10.853 --> 00:30:16.813
I replaced the whole team by top leaders with decades of experience in drug discovery and development.
00:30:16.813 --> 00:30:23.712
And my CMO is in North Carolina, my chief technology officer is in New Jersey, and et cetera.
00:30:23.712 --> 00:30:27.833
And when I fly into Needham, Massachusetts, where I also live, right?
00:30:28.833 --> 00:30:31.932
my team also fly, flies in, and we are very close.
00:30:31.982 --> 00:30:39.583
We have a very close community, and we have leadership team dinners and happy hours and town hall meetings, and I have all my one-on-one meetings.
00:30:39.633 --> 00:30:43.803
And here is the beauty of this hybrid model that I've always embraced actually.
00:30:44.163 --> 00:30:54.353
That when I'm there to strongly support the culture, to help to build trust in person, wh-which you cannot do on the same level by Zoom or Teams to have fun together.
00:30:54.393 --> 00:30:56.663
But everybody can also come with their concerns.
00:30:56.682 --> 00:30:57.813
My door is open.
00:30:58.232 --> 00:31:06.596
But it also means that you are in a reactive mode When I am working remotely, I'm in a more strategic way, I have the...
00:31:06.606 --> 00:31:20.502
Let's say when I'm working from, Continental Europe then I have the mornings for real focus time while the American co-employees are still asleep they wake up with the revisions to the documents that they sent me when I went to sleep.
00:31:20.502 --> 00:31:24.682
So actually it may enhance, efficiency quite significantly.
00:31:25.133 --> 00:31:30.083
But also it really helps to drive a strategic distant mindset.
00:31:30.083 --> 00:31:39.073
And I've done this when I was at GSK because I led the global operation, and that means that by definition you are always remote, right?
00:31:39.083 --> 00:31:54.403
When I wo- worked from England where the headquarters are from GSK, then I was not at the same time, in that say, Upper Providence, where we had a very big operation in Pennsylvania, or I was not in Cambridge, Massachusetts, where I led Tempero Pharmaceuticals.
00:31:55.343 --> 00:32:02.722
and the other way around, when I worked from the US I was not in Stevenage where we had a very big scientific hub, and I was the site head of Stevenage.
00:32:02.762 --> 00:32:09.073
Actually, in the late'90s I worked at UCSD in California so this is a long time ago.
00:32:09.373 --> 00:32:16.952
And I still led an academic group at the Leiden University Medical Center in the Netherlands, and we had nine hours of time difference.
00:32:17.032 --> 00:32:18.893
This was before T- Teams and Zoom,
00:32:19.133 --> 00:32:19.633
Yeah
00:32:19.803 --> 00:32:21.843
email and telephones obviously.
00:32:22.583 --> 00:32:33.633
and actually this was one of the most productive times both for the UCSD team and for my team in Leiden because we could work around the clock actually exactly as I just described.
00:32:33.643 --> 00:32:43.163
So it is critical to spend sufficient time
together, to have this strong trust, trusting relationship and to be able to listen to people.
00:32:43.883 --> 00:32:46.813
but at the same time, there's a benefit, I think, of being remotely.
00:32:46.813 --> 00:32:50.252
So everybody is invited to work in a hybrid model
00:32:50.906 --> 00:32:51.217
I love that.
00:32:51.237 --> 00:32:57.217
And this, what has really come through in this talk is one, the mission-focused putting pa- putting patients first, right?
00:32:57.366 --> 00:33:06.817
Importance of culture, and it seems like with those two things in place, that allows a level of strategic work, a level of trust where you don't necessarily...
00:33:07.426 --> 00:33:19.126
y- when you're together, you're productive, you're doing the things that make sense when you're together, but you're not it's not a return to office situation where people are checking in, having lunch in the cafeteria, and then badging out so they don't get in trouble with their managers.
00:33:19.480 --> 00:33:20.621
E-e-exactly.
00:33:20.621 --> 00:33:26.060
I'm very much a fan of the principle of freedom and accountability.
00:33:26.080 --> 00:33:27.951
That should go hand in hand, right?
00:33:28.058 --> 00:33:32.019
These are senior leaders, they're scientists, they're professionals.
00:33:32.058 --> 00:33:36.638
S-sometimes they're even parents of children, and I should not treat them like children.
00:33:36.679 --> 00:33:39.598
I'm interested in, their performance.
00:33:39.669 --> 00:33:40.088
Yes
00:33:40.229 --> 00:33:40.959
do they deliver?
00:33:41.449 --> 00:33:46.558
I'm interested in their behaviors and their cultural values and ethical standards, all of that.
00:33:47.088 --> 00:33:48.338
And that's what we measure, right?
00:33:48.429 --> 00:33:49.909
And we we are a company of...
00:33:49.959 --> 00:33:52.019
we are growing, but in a measured way.
00:33:52.019 --> 00:33:54.308
Maybe we have 80, people.
00:33:54.719 --> 00:33:58.999
We actually had the output of a mid-sized pharma company during the last f- few years.
00:33:59.009 --> 00:34:04.739
If you compare us to comparable companies in this space, they typically have 500 employees.
00:34:04.772 --> 00:34:05.173
Yeah
00:34:05.318 --> 00:34:07.078
Nobody should complain about performance.
00:34:07.078 --> 00:34:13.949
This model of giving people the, combination of freedom and accountability is the right model as I see it.
00:34:15.058 --> 00:34:17.278
I've e-even done a little thought experiment.
00:34:17.278 --> 00:34:26.648
At some point, I saw that other companies after the pandemic to implement rules like you have to be in the company at least three days a week.
00:34:26.780 --> 00:34:28.550
So then we looked into it, right?
00:34:28.590 --> 00:34:35.020
And thought for people who work in the lab, this is completely wrong because actually they should be in the office every day.
00:34:35.120 --> 00:34:45.780
For let's say, clinical trial associates who do audits in the clinical trial centers, because we've overseen a lot of our clinical trials ourselves before we started to work with the CRO.
00:34:45.830 --> 00:34:48.660
That's also not the right answer because they should not be in the office.
00:34:48.690 --> 00:34:50.210
They should be on the road, actually.
00:34:50.620 --> 00:34:58.820
So we try to do it based on judgment, and we overlay AI, artificial intelligence, with what I call RI, which is real intelligence
00:34:59.678 --> 00:35:00.068
I love it.
00:35:00.128 --> 00:35:00.488
All right.
00:35:00.748 --> 00:35:04.618
Sounds like that could probably be a whole nother conversation, but I think I've kept you long enough today.
00:35:04.838 --> 00:35:06.398
So thank you very much for joining me.
00:35:06.418 --> 00:35:07.188
That was wonderful.
00:35:07.980 --> 00:35:09.060
It was great talking to you.
00:35:09.080 --> 00:35:10.230
Thank you for your time, Jonathan